Pharmacology of Vanilloid Transient Receptor Potential Cation Channels

Joris Vriens, Giovanni Appendino, and Bernd Nilius

Department of Molecular Cell Biology, Division of Physiology, Campus Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium (J.V., B.N.); and Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche, Università del Piemonte Orientale, Novara, Italy (G.A.)

Received February 16, 2009; accepted March 17, 2009

ABSTRACT

Depending on their primary structure, the 28 mammalian transient receptor potential (TRP) cation channels identified so far can be sorted into 6 subfamilies: TRPC (“Canonical”), TRPV (“Vanilloid”), TRPM (“Melastatin”), TRPP (“Polycystin”), TRPML (“Mucolipin”), and TRPA (“Ankyrin”). The TRPV subfamily (vanilloid receptors) comprises channels critically involved in nociception and thermosensing (TRPV1, TRPV2, TRPV3, and TRPV4), whereas TRPV5 and TRPV6 are involved in renal Ca\(^{2+}\) absorption/reabsorption. Apart from TRPV1, the pharmacology of these channels is still insufficiently known. Furthermore, only few small-molecule ligands for non-TRPV1 vanilloid receptors have been identified, and little is known of their endogenous ligands, resulting in a substantial “orphan” state for these channels. In this review, we summarize the pharmacological properties of members of the TRPV subfamily, highlighting the critical issues and challenges facing their “deorphanization” and clinical exploitation.

Transient receptor potential (TRP) cation channels are unique cellular sensors characterized by a promiscuous activation mechanism (Pedersen et al., 2005; Voets et al., 2005; Ramsey et al., 2006; Nilius et al., 2007). More than 50 members of the TRP family have been characterized in yeast, worms, insects, fish, and mammals (Vriens et al., 2004a; Nilius and Voets, 2005), making them one of the largest groups of ion channels. The 28 mammalian TRPs identified so far can be sorted out into 6 subfamilies: TRPC (“Canonical”), TRPM (“Melastatin”), TRPV (“Vanilloid”), TRPA (“Ankyrin”), TRPP (“Polycystin”), and TRPML (“Mucolipin”) (Fig. 1). TRPs are classified essentially according to their primary amino acid sequence rather than selectivity or ligand affinity, because their properties are heterogeneous and their regulation is complex. From a structural standpoint, TRP channels are membrane proteins with six putative transmembrane spans (TMs) and a cation-permeable pore region formed by a short hydrophobic stretch between TM5 and TM6. The structural differences within the TRP subfamilies have been recently reviewed (Owsianik et al., 2006), and

This work was supported by the Belgian Federal Government; the Flemish Government; and the Onderzoeksraad Katholieke Universiteit Leuven [Grant GOA 2004/07, Fonds voor Wetenschappelijk Onderzoek G. 0136.00; Fonds voor Wetenschappelijk Onderzoek G. 0172.03, Interuniversity Poles of Attraction Program, Prime Ministers Office IUAP Nr.3P4/23, and Excelentiefinanciering EF/95/010].

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

ABBREVIATIONS: TRP, transient receptor potential; TM, transmembrane domain; TRPV, transient receptor potential receptor vanilloid; AEA, N-arachidonylethanolamine; NADA, N-arachidonoyldopamine; RTX, resiniferatoxin; TG, trigeminal; DRG, dorsal root ganglia; 2-APB, 2-aminoethoxydiphenyl borate; RR, ruthenium red; OLEA, N-oleoylethanolamine; HPETE, hydroperoxyeicosatetraenoic acid; HEK, human embryonic kidney; IP\(_3\), inositol triphosphate; CGRP, calcitonin gene-related peptide; PIP2, phosphatidylinositol biphosphate; PKA, protein kinase A; PI(3), phosphatidylinositol 3 triphosphate; PAR2, protease-activated receptor 2; QX-314, 2-((2,6-dimethylphenyl)amino)-N,N,N-triethyl-2-oxoethanaminium; DPTHF, 2,2-diphenyltetrahydrofuran; DPBA, diphenylboronic anhydride; PLA2, phospholipase A2; EET, epoxyeicosatrienoic acid; BAA, bisandrogapholide A; PLC, phospholipase C; OAG, 1-oleoyl-sn-glycerol; PTH, parathyroid hormone; DD161515, N-[2-(N-methylpyrrolidinyl)ethyl]glycyl]-N-[2,4-dichlorophenethyl]glycyl]-N-[2,4-dichlorophenethyl]glycinamide; U73122, 1-[6-((17 β,3-methoxyster-1,3,5(10)-tien-17-y)amino)hexyl]-1H-pyrrole-2,5-dione; RN-1734, 1-alkoxycarbonylalkylidenetriphenyarsoranes.
TRP proteins are essentially cation-permeable ion channels sensitive to a remarkable range of stimuli. Genetic approaches in worms, flies, and mice have demonstrated the involvement of TRPs in a variety of sensory processes that include thermosensation, osmosensation, olfaction, taste, mechanosensation, vision, and pain perception. Remarkably, mutations in different TRPs have also been linked to human diseases (Nilius et al., 2007).

Because TRPV1 is exquisitely sensitive to chemical gating, it seems reasonable to assume that small molecules, selective ligands, and endogenous ligands also exist for other TRPs, in particular for those from the vanilloid subclass (TRPVs). However, the search for these compounds has so far been largely elusive, even for the TRPs more closely related to TRPV1. In this review, we discuss the major reasons responsible for the orphan state of so many TRPs and review the current state of the pharmacological modulation of TRPV and the clinical potential of their manipulation.

TRPV1

The vanilloid receptor 1, or TRPV1, the founding member of the mammalian TRP channels, was identified in expression cloning experiments using capsaicin (compound 1) (Figs. 2–7) from hot pepper as a probe. Given the involvement of many TRPs in sensation and taste, it is not surprising that a compound of dietary origin was the first ligand to be discovered for this class of proteins. TRPV1 is a nonselective cation channel with a preference for calcium and is activated by noxious stimuli, heat, protons, pH <5.9, and various, mostly obnoxious, natural products (Tominaga et al., 1998). TRPV1 is predominantly expressed in sensory neurons (Caterina et al., 1997) and is believed to play a crucial role in temperature sensing and nociception (Caterina et al., 2000), qualifying therefore as a molecular target for pain treatment. Thanks to the availability of a wealth of TRPV1 ligands, this ion channel is also the best-characterized member of the TRPV subfamily in terms of expression pattern, properties, and clinical translation of its manipulation (Vennekens et al., 2008).

TRPV1 Agonists

A distinction should be made between direct activators of TRPV1 and sensitizers. Strictly speaking, capsaicin and its biological analogs isolated from plants and animals are essentially sensitizers, because they act by lowering the thermal “physiological” activation threshold of TRPV1. Nevertheless, because these compound bind directly to TRPV1, they are conveniently considered as direct activators, in contrast to compounds that do not bind TRPV1 and affect its functioning indirectly, which are referred to as sensitizers. Because of the large body of literature on TRPV1 ligands, only the most important chemotypes and the most recent additions are discussed here (Appendino et al., 2008), covering in a more exhaustive way the issue of the topology of the vanilloid binding site.

Endogenous Agonists. Good evidence has been presented on the existence of endogenous vanilloid agonists, a class of compounds referred to as endovanilloids, and on their capability to modulate the sensitivity of TRPV1 channels to thermal stimuli (Van Der Stelt and Di Marzo, 2004). Various lipids from the fatty acid pool have also been identified as TRPV1 activators. These compounds can be divided into conjugates of biogenic amines [e.g., N-arachidonylethanolamine (AEA, anandamide, 2a), N-arachidonoyldopamine (NADA, 3a), N-oleylethanolamine (OLEA, 2b), N-arachidonolylserine, and various N-acyltaurines and N-acylsalsolinols (Appendino et al., 2008) and oxygenated eicosatetraenoic acids (Ahern, 2003; Wang et al., 2005)] like the lipoxygenase products 5-, 12-, and 15-hydroperoxyicosatetraenoic acids (5S-, 12S-, 15S-HPETE, 4a–6a) (Hwang et al., 2000), their reduced hydroxyl analogs (4b–6b), prostaglandins, and leukotriene B4 (Huang et al., 2002). In addition, adenosine, ATP, and polyamines (such as spermine, spermidine, and putrescine) activate TRPV1, as well as acidic conditions, pH <5.9, like those observed during inflammation (Szallasi and Di Marzo, 2004; McNamara et al., 2005; Xu et al., 2005; Ahern et al., 2006; Alexander et al., 2006; Siemens et al., 2006).

Endovanilloids of the fatty acid conjugate-type resemble capsaicinoids for the presence of a polar head and a lipophilic moiety linked by an amide group, but the polar head is generally aliphatic [ethanolamine in AEA (2a) and OLEA (2b)] or if aromatic, as in NADA (3a) (Hwang et al., 2000), is not of the guaiacyl but of the catechol type (NADA, 3a). Within this class of compounds, the term vanilloid is therefore devoid of structural meaning and refers exclusively to their biological profile.

Endovanilloids are promiscuous agents. Thus, AEA (2a) and NADA (3a) bind not only TRPV1 but also cannabinoid receptors, whereas OLEA (2b) also bind peroxisome proliferator-activated receptors. Within the many synthetic ana-

![Fig. 1. Phylogenetic relations of the mammalian TRPV channels and their related other TRP subfamilies (polycystin TRPPs, canonical TRPCs, melastatin TRPMs, ankyrin TRPAs, and mucolipin TRPMLs). This consensus tree was obtained as described in detail in Yu and Catterall (2004) from an analysis of the pore regions. The scale bar corresponds to the number of changes in amino acids needed to explain the differences in the protein sequences. Note the distance between the highly Ca²⁺-permeable TRPV5, TRPV6, and the thermoTRPs, TRPV1 to -4. (For more details, see also Yu and Catterall, 2004; Montell, 2005; Nilius et al., 2007; and Vennekens et al., 2008.)](https://molpharm.aspetjournals.org/article-pdf/1263/1263/1263/33178132/0431749.pdf)
logs of endovanilloids, of special interest are the methylated forms of $N$-oleoyldopamine (3b), because reversal of activity from agonist to antagonist is observed upon $O$-methylation of the catechol system, with 3-methyl-$N$-oleoyldopamine (3c) acting as an agonist and 4-methyl-$N$-oleoyldopamine (3d) as an antagonist (Almási et al., 2008).

Fig. 2. Formulas of compounds 1 to 7a,b.

Fig. 3. Formulas of compounds 8 to 20.
Polyamines are important endogenous regulators of TRPV1 channels that are capable of modulating inflammation and nociception. Extracellular spermine, spermidine, and putrescine directly activate TRPV1 in a charge-dependent manner, both in heterologous expression systems and in sensory neurons. The threshold for activation by spermine is rather high (~500 μM at room temperature), but spermine can enhance capsaicin-evoked currents with an EC50 value of approximately 5 μM. Experiments with TRPV1 mutants have identified extracellular acidic residues critical for polyamine regulation. Thus, neutralization of Asp646 abolished direct activation by spermine, whereas neutralization of this acidic residue or Glu648 inhibited spermine-induced sensitization. These data show that polyamines, by virtue of their cationic charge, can regulate the activity of TRPV1 at physiological concentrations (Ahern et al., 2006).

Exogenous Agonists of Natural, Semisynthetic, and Synthetic Origin. TRPV1 can be activated by a heterogeneous array of natural products that includes both dietary compounds [capsaicinoids (7a) and capsinoids (7b), piperine (8), eugenol (9), and gingerol (10)], plant toxins [resiniferatoxin (RTX, 11a)], and animal toxins (Vriens et al., 2008). Capsaicinoids and capsinoids occur in plants from the genus Capsicum and are typical of hot (chili) and nonpungent (bell)
peppers, respectively. More than 12 pungent capsaicinoids have been characterized from hot peppers and three major nonpungent capsinoids from bell peppers (Appendino, 2007). Capsaicinoids and capsinoids are characterized by an oxygenated vanillyl aromatic moiety bound via an amide (capsaicinoids) or ester (capsinoids) linker to a lipophilic acyl group. The vanillyl and the carbonyl linker contain polar groups capable of forming hydrogen bonds essential for activity, whereas the lipophilic moiety interacts with a corresponding cleft of the vanilloid binding site of TRPV1. Replacement of the medium-sized branched fatty acid of capsaicin with longer fatty acids is detrimental for activity (Morita et al., 2006), but remarkably, the presence of unsaturations restores and potentiates activity, as exemplified by oleoylanillamine (12a, olvanil), a compound 10-fold more potent than capsaicin in TRPV1 activation assays (Appendino et al., 2002) (Table 1). A further increase of potency was obtained by the introduction of polar functions on the acyl moiety of olvanil, as discovered for phenylacetylvinvanil (12b), the most potent capsaicinoid reported to date (~500-fold more potent than capsaicin) (Appendino et al., 2005b). Capsiates are at least 1 order of magnitude less potent TRPV1 activators than capsaicin, but their lack of pungency is nevertheless puzzling. Unlike capsaicin, capsiates are hydrolytically unstable, and it has been suggested that they act essentially as prodrugs of vanillic alcohol (Rosa et al., 2005).

Fig. 6. Formulas of compounds 41 to 43.

Fig. 7. Formulas of compounds 44 to 59.
Piperine (8) belongs to a group of alkaloid typical of plants from the Piperaceae family, like black pepper (Piper nigrum L.), a most popular spice. Piperine shows putative anti-inflammatory activity, may promote digestive processes, and might increase the absorption of branched amino acids and several classes of small molecules of dietary and phytotherapy relevance (Srinivasan, 2007). The first evidence that piperine is a TRPV1 agonist was the demonstration of its ability to inhibit the binding sites of [3H]RTX in the dorsal horn of pig spinal cord (Szallasi et al., 1991). In addition, piperine activates inward currents in TG neurons, an action that was found to be sensitive to capsazepine (Liu and Simon, 1996). In a more recent study, Gunthorpe and coworkers concluded that piperine is not only similar to capsaicin in its effects at human TRPV1 expressed in HEK293 cells but also exhibits a greater efficacy than capsaicin itself for both activation and desensitization of TRPV1 (McNamara et al., 2005). The reasons for the improved desensitization-to-excitation ratio of piperine compared with capsaicin are unclear. From a structural standpoint, there are three major differences between capsaicin and piperine, namely the replacement of the guaiaacyl moiety with a methylenedioxy group, a structural element associated with the inhibition of cytochrome P450 metabolism (Srinivasan, 2007), the presence of the aromatic moieties on the acyl and not the amine moiety, and the insertion of a four-carbon butadienyl linker between the amide and the aromatic moiety (Reen et al., 1996). An attractive hypothesis to explain the pharmacodynamic differences between capsaicin and piperine is that the latter might be a better inducer of dephosphorylative inactivation of TRPV1 (see below). Clearly, piperine is an attractive lead for the synthesis of improved TRPV1 agonists, but surprisingly, very little is known about its structure-activity relationships.

Eugenol (9), an allyl chain-substituted guaiacol, is a member of the allylbenzene class of phenylpropanoids. It is the major constituent of clove oil from Eugenia caryophyllata L. Electrophysiological studies have shown that eugenol is able to activate inward currents in hTRPV1-HEK293 cells and TG neurons. This effect was completely prevented by the TRPV1 antagonist capsazepine, demonstrating the involvement of TRPV1 (Yang et al., 2003).

Within nondietary naturally occurring vanilloids, a special position is held by resiniferatoxin (11a) from the dried latex of Euphorbia resinifera. The vanillyl group is critical for the activity of both capsaicin and RTX. This has led to the widespread use of the term “vanilloids” to refer to TRPV1 ligands. RTX is 3 to 4 orders of magnitude more potent than capsaicin both in terms of dose-response curve and effect on thermo-regulation and neurogenic inflammation (Szallasi and Blumberg, 1989) (Table 1). RTX is structurally more complex than capsaicin, and its structure-activity relationships are still largely unknown. The methylene linker between the side chain of the aromatic ring and the carbonyl is critical, as are the C-3 carbonyl on ring A and the orthoester moiety in ring C of the diterpenoid core (Appendino et al., 2007). In addition, camphor (13), isolated from the wood of the camphor laurel tree (Cinnamomum camphora L.), can activate heterologously expressed TRPV1. Activation of rat TRPV1 by camphor is mediated by a distinct channel region from capsazepine because it is insensitive to the competitive TRPV1 antagonist capsazepine. Camphor activates TRPV1 less effectively than capsaicin (Table 1) but in a more rapid and complete way. However, camphor is a nonselective TRPV1 agonist because it also activates other TRP channels, including TRPV3 (Xu et al., 2005).

Spiders and jellyfish venoms are a major source of TRPV1 activators of animal origin. The presence of inhibitor cysteine knot peptides is the hallmark of venoms from Indian tarantulas, and three of these peptides, cogeten named vanillo-toxins, have been shown to activate TRPV1 (EC_{50} values \sim 10^{-8} to 10^{-4} M). TRPV1-mediated pain and inflammation are undoubtedly part of the mechanism by which animals avert predators (Siemens et al., 2006). From the marine front, the burning pain sensation caused by venom from the tentacles of certain cnidarians has been suggested to be mediated by the removal (or inhibition) of TRPV1 desensitization, although the clear mechanism is still uncertain (Cuypers et al., 2006). However, the active principle(s) of these venoms is still unknown (peptide versus bioactive small molecule), and their precise site of interaction remains to be elucidated (TRPV1 itself versus its signal-transduction pathway). The study of offensive animals has surely the potential to provide new probes to investigate TRPV1, but the field has not yet been systematically investigated. Finally, TRPV1 is also activated by the synthetic agent 2-aminoethoxydiphenyl borate (2-APB) (EC_{50} value \sim 10^{-4}M), a blocker of store-operated Ca^{2+} entry and IP_{3} receptors (Alexander et al., 2006).

Several synthetic drugs have been shown to interact with TRPV1. Thus, a surprising finding was the observation that the local anesthetic lidocaine (14) activates TRPV1, and, somewhat less efficiently, TRPA1, both in heterolog systems and in native rodent dorsal root ganglion sensory neurons. Lidocaine also induced a TRPV1-dependent release of calcitonin gene-related peptide (CGRP) from isolated skin and peripheral nerve. Activation of TRPV1 by lidocaine required segments of the putative vanilloid-binding domain within

### Table 1

<table>
<thead>
<tr>
<th>TRPV1 agonists</th>
<th>Compound</th>
<th>Compound Number</th>
<th>EC_{50} \text{ M}</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endogenous agonists (fatty acids)</td>
<td>Anandamide</td>
<td>2a</td>
<td>\text{10}^{-5}</td>
<td>Rat</td>
<td>Ahern (2003)</td>
</tr>
<tr>
<td></td>
<td>NADA</td>
<td>3a</td>
<td>\text{10}^{-5} to \text{10}^{-7}</td>
<td>Human and rat</td>
<td>Huang et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>12S-HPETE</td>
<td>5a</td>
<td>\text{10}^{-5}</td>
<td>Human and rat</td>
<td>Hwang et al. (2000)</td>
</tr>
<tr>
<td>Exogenous agonists of natural, semisynthetic and synthetic origin</td>
<td>Capsaicin</td>
<td>1</td>
<td>\text{10}^{-6} to \text{10}^{-9}</td>
<td>Rodent</td>
<td>Caterina et al. (1997)</td>
</tr>
<tr>
<td></td>
<td>Piperine</td>
<td>8</td>
<td>\text{10}^{-5} to \text{10}^{-4}</td>
<td>Human</td>
<td>Liu and Simon (1996)</td>
</tr>
<tr>
<td></td>
<td>Eugenol</td>
<td>9</td>
<td>\text{10}^{-5} to \text{10}^{-9}</td>
<td>Human</td>
<td>Yang et al. (2003)</td>
</tr>
<tr>
<td></td>
<td>Resiniferatoxin</td>
<td>11a</td>
<td>\text{10}^{-10} to \text{10}^{-8}</td>
<td>Rat</td>
<td>Szallasi and Blumberg (1989)</td>
</tr>
<tr>
<td></td>
<td>Olvanil</td>
<td>12a</td>
<td>\text{10}^{-10} to \text{10}^{-9}</td>
<td>Human</td>
<td>Appendino et al. (2005b)</td>
</tr>
<tr>
<td></td>
<td>Phar</td>
<td>12b</td>
<td>\text{10}^{-10} to \text{10}^{-9}</td>
<td>Human</td>
<td>Appendino et al. (2005b)</td>
</tr>
<tr>
<td></td>
<td>Camphor</td>
<td>13</td>
<td>\text{10}^{-2}</td>
<td>Rat</td>
<td>Xu et al. (2005)</td>
</tr>
</tbody>
</table>
TRPA1, TRPV1 is activated by pungent extracts from garlic ligand-sensitive elements of TRPV channels. Thus, like mutation of a cysteine residue in the N terminus (Cys157) is induced neurotoxicity (Leffler et al., 2008).

The modulation of TRPV1 signaling by covalent modification of a cysteine residue in the N terminus (Cys157) is complementary to the use of molecular probes to map the ligand-sensitive elements of TRPV channels. Thus, like TRPA1, TRPV1 is activated by pungent extracts from garlic and onion and their active component allicin (15) and alliiin (16). These agents activate TRPV1 by covalent modification of one single cysteine residue (Cys157) via Michael addition. Consistent with this mechanism, treatment with dithiothreitol, a disulfur exchange agent, produced a near-complete reversal of activation by allicin. 2-Aminoethylmethane thiosulfonate hydrobromide sensitized the channel to capsaicin (Salazar et al., 2008), and it is therefore not surprising that mustard oil has been described as an activator of TRPV1 (in the millimolar range) (Ohta et al., 2007). Also a series of membrane-permeable oxidizing agents like diamide, chloramine-T, and copper (0) complexes can enhance the heat activation of TRPV1 by irreversible covalent modification of sulfhydryl groups. Extracellular application of the membrane-impermeable reducing agent glutathione mimicked the effects of dithiothreitol in potentiating the heat TRPV1 responses, suggesting that redox-active substrates can directly modulate channel activity at sites of both extracellular and cytoplasmic location (Susankova et al., 2006).

The burning and irritation induced by capsaicin and related vanilloids represent a major shortcoming for the therapeutic use of these compounds. In addition, loss of the homovanillyl ester group of RTX would generate the tumorigenicity diterpenoid ROPA (17), an issue that so far has been largely unaddressed. The development of more potent, orally active vanilloids like olvanil (Alexander et al., 2006), SDZ-249482 (18a), and SDZ-249665 (18b) did not fully circumvent the discomfort of the side effects derived from irritation. In parallel to the identification of novel vanilloid agonists, research on the clinical translation of this class of compounds has also focused on innovative formulations for topical application as analgesics. In this context, the vanilloid analog DA-5018 (capsavanil, 19) and zucapsaicin (20) are currently being developed for this indication (Messegue et al., 2006).

Ligand-Binding Site on TRPV1. In sharp contrast to other ligand-gated channels that produce fast synaptic transmission, vanilloids show slow activation kinetics, in part because their binding site is located in the intracellular portion of the receptor. Capsaicinoids, resiniferonoids, and endovanilloids are highly lipophilic compounds and must therefore cross the cell membrane to act on their intracellular binding site(s) on TRPV1. In fact, charged capsaicin analogs cannot cross the cell membrane and are only effective when applied to the intracellular surface (Jung et al., 1999). The dynamic of this process is largely unknown, but its relevance is highlighted by comparison between olvanil and its saturated analog (N-stearoylvanillamide, 12c) that is at least 5 orders of magnitude less potent as a TRPV1 ligand, presumably because of a very slow kinetics of penetration into the cell (Appendino et al., 2002).

Information on the ligand binding site of TRPV1 has recently surfaced. Molecular modeling studies on the xenovanilloid capsaicin (1) and the endovanilloid 12S-HPETE (5a) have suggested the sharing of specific amino acid residues in TRPV1 binding by these compounds (Hwang et al., 2000). A different approach was pursued by Julius and coworkers (Jordt and Julius, 2002), who capitalized on the observation that avian TRPV1 is heat- and proton-sensitive but capsaicin-insensitive to get clues as to the location of the capsaicin-binding site. Thus, comparison of the primary structure of the human and the avian isoforms of TRPV1 and mutational studies revealed a critical role for Tyr511 and Ser512, located at the transition between the second intracellular loop and TM3, confirming that the vanilloid binding site is located intracellularly (Jordt and Julius, 2002). By analyzing mammalian interspecies TRPV1 chimeras and site-directed TRPV1 mutants, a third critical residue in the putative TM4 segment (Met547 in rat, Leu547 in human and rabbit, Leu549 in guinea pig) was identified. These studies have benefited on the availability of isomeric-specific ligands, like phorbol 12-phenylacetate 13-acetate 20-homovanillate (21), an agonist selective for rat TRPV1, and of vanilloid antagonists like capsazepine (22) (Chou et al., 2004; Gavva et al., 2005). Tyr550 in rat and human also seems to contribute to vanilloid binding (Gavva et al., 2005), whereas Arg114 and Glu761 in the N and C termini, respectively, are involved in the different ligand sensitivity of TRPV1 and TRPV2. The loss of proton activation in these mutants suggests that both residues may play a role in the general activation by agonists. The scattered distribution, in terms of primary structure, of the aminoacyl residues necessary for capsaicin binding suggests that in the tertiary and quaternary structure of the native channel, these critical residues are relatively close to each other. Possibly other unidentified regions required for capsaicin binding might also exist.

The current helix-packing models of the voltage-gated K+ channels, as derived from helical periodicity analysis and crystallographic approaches, show that the first, second, and third TM domains are located on the lipid-facing periphery of the tetrameric channel complex, whereas the fifth and sixth TM domains are located closer to the pore-forming channel core. Assuming similar helix-packing also for TRPV1, the lipophilic moiety of capsaicin may bind to the second and third TM domains on the channel-lipid interface, whereas the vanilloid moiety may interact with residues around Tyr511 in the cytosolic region, thus linking the two TM domains together with the cytosolic tail. The structural determinants involved in capsaicin binding are, overall, still poorly defined, but several molecular models for the vanilloid site have been proposed, which, upon refinement and validation, may facilitate the design of agonists with better therapeutic index than the current ligands.

Extracellular protons are believed to act primarily by increasing the probability of channel opening rather than by altering unitary conductance or interacting directly with the vanilloid-binding site (Baumann and Martensson, 2000). Acid solutions evoke ionic currents with an EC50 ~pH 5.4 when applied to outside-out but not inside-out membrane patches excised from HEK293 cells expressing TRPV1 (Baumann and Martensson, 2000). This observation suggests that protons act on amino acid(s) located in the extracellular domain of TRPV1, presumably causing protonation of one or more critical carboxylates. Surprisingly, TRPV1 is also activated by
gadolinium (III) ions (EC_{50} value ~72 μM at +40 mV), an effect that requires the pore residues Glu600 and Glu648, two protonation sites close to the selectivity filter. Cd^{2+} also potentiates TRPV1 activation by capsaicin, and the two effects (activation and potentiation) might be related to the neutralization of specific proton binding sites (Tousova et al., 2005).

Sensitizers. One important aspect of TRPV1 regulation that has received considerable attention concerns the mechanisms by which the inflammatory mediators in damaged tissues sensitize TRPV1 to its chemical and physical stimuli. Whereas capsaicin acts directly on TRPV1, others influence TRPV1 indirectly, via receptors of intrinsic tyrosine kinase pathways, G-protein-coupled receptors, or receptors coupled to the Janus tyrosine kinase/signal transducer and activator of transcription signaling pathway. Like other ion channels, TRPV1 can be phosphorylated by kinases including PKA (Bhave et al., 2002), protein kinase C (PKC; Bhave et al., 2003), Ca^{2+}/CaM-dependent kinase II (Jung et al., 2004), or Src kinase (Jin et al., 2004). TRPV1 activity is also strongly modulated by phosphorylidyinositol phosphates. Indeed, PIP2 seems to be associated constitutively with TRPV1 (Nilius et al., 2008).

PKA plays a pivotal role in the development of hyperalgesia and inflammation by inflammatory mediators. Ser116 and Thr370 in the amino terminus of TRPV1 are reportedly phosphorylated by PKA and are involved in desensitization (Mohapatra et al., 2003), whereas phosphorylation of Ser116 by PKA inhibits dephosphorylation of TRPV1 caused by capsaicin exposure.

PKC-dependent phosphorylation of TRPV1 occurs downstream from the activation of G_{q-}coupled receptors by several inflammatory mediators, including ATP, bradykinin, prostaglandins, and trypsin or trypptase (Tominaga et al., 2001; Sugira et al., 2002; Moriyama et al., 2003). PKC-dependent phosphorylation of TRPV1 not only potentiates capsaicin- or proton-evoked responses but also reduces the temperature “threshold” for TRPV1 activation so that normally nonpainful temperatures in the range of normal body temperature become capable of activating TRPV1 and generate a sensation of pain. Direct phosphorylation of TRPV1 by PKC has been located at Ser502 and Ser800 (Bhave et al., 2003), but the precise isoform of PKC responsible for TRPV1 sensitization in sensory neurons has not yet been identified.

Additional calciuninhibits desensitization of TRPV1, indicating that a phosphorylation/dephosphorylation process is important for TRPV1 activity. Indeed, Ca^{2+}/CaM-dependent kinase II reportedly controls TRPV1 activity upon phosphorylation of TRPV1 at Ser502 and Thr704 by regulating capsaicin binding (Jung et al., 2004). Phosphorylation of TRPV1 by three different kinases seems therefore to control channel activity, dynamically balancing phosphorylation and dephosphorylation.

Sensitization by PKC seems to involve increased exocytotic delivery of TRPV1 to the plasma membrane (Morenilla-Palao et al., 2004). Likewise, insulin and insulin-like growth factor-I increase translocation of TRPV1 to the plasma membrane via activation of receptor tyrosine kinases, which, in turn, leads to PI(3) kinase and PKC activation (Van Buren et al., 2005). Neurotrophic factors, such as nerve growth factor, glia-derived growth factor, and neurotropin 3, also increase the number of TRPV1 expressing neurons in sensory ganglia, elevate TRPV1, and increase the response to capsaicin in single DRG neurons. This “neurotrophic factor-induced gain of TRPV1 function” may relate to the pathophysiological significance of TRPV1, generating pain during tissue repair and growth (Amadesi et al., 2006).

Activation of TRPV1 is potentiated by stimulation of the metabotropic 5-hydroxytryptamine (5HT) receptors 5HT_{2a, R} and 5HT_{7}. 5HT is released in injured and inflamed tissues and causes hyperalgesia. This potentiation is due to 5HT receptor-mediated activation of PKA and PKC (Ohta et al., 2006). NGF potentiates TRPV1 activation via binding to its TrkA receptor. This effect is attenuated by wortmannin, a PI(3) kinase inhibitor. PI(3) kinase is directly bound to TRPV1 via its p85 binding, as shown elegantly by total internal reflection fluorescence. An increased plasma membrane insertion of functional TRPV1 is induced, leading to a potentiation of currents through these channels and ultimately causing thermal hyperalgesia by proalgesic agents as NGF (Stein et al., 2006). However, PI(3)K binding to TRPV1 does not seem to be promoted by NGF and does not result in TRPV1 tyrosine phosphorylation (as shown for Tyr199; Zhang and McNaughton, 2006).

Within eicosanoids, prostaglandin E2 and prostacyclin sensitize TRPV1 through EP2 or EP4 receptors and PKC activation. Furthermore, a PKA-sensitive pathway for TRPV1 activation via EP4 and IP receptors (prostaglandin E2 and prostacyclin) has also been postulated (Moriyama et al., 2005).

TRPV1 is sensitized by activation of the protease-activated receptor 2 (PAR2) (Amadesi et al., 2004). PAR2 colocalizes with PKCe and PKA and, upon stimulation, causes PKCe- and PKA-dependent activation of TRPV1 (Amadesi et al., 2006), ultimately triggering the thermal hyperalgesia that underlies inflammatory pain (Elitt et al., 2006; Surprenant, 2007).

The cyclin-dependent kinase CdK5 plays an important role in pain transduction and nociceptive signaling (Pareek and Kulkarni, 2006; Pareek et al., 2006). Thr407 in TRPV1 can be directly phosphorylated by CdK5, whereas inhibition of CdK5 activity decreases TRPV1 function and Ca^{2+} influx. Interestingly, the CdK5 conditional knockout mouse shows hypoalgesia (Pareek et al., 2007).

A variety of 1,4-dihydropyridines have been developed as novel “enhancers” of TRPV1 activity. These compounds could increase the maximal capsaicin effect on Ca^{2+} uptake in DRGs. The 1,4-dihydropyridine enhancers contain a 6-aryl substitution, alkyl groups at the 1 and 4 positions, and a 3-phenylalkylthioester (Roh et al., 2008).

General anesthetics (gas [e.g., isoflurane, sevoflurane, enflurane, and desflurane]) sensitize TRPV1 at clinically relevant concentrations in a process that can exacerbate postsurgical pain and inflammation (Cornett et al., 2008; Harrison and Nau, 2008). In addition, tramadol activates TRPV1, and it has been suggested that the “unexpected” local side effects of this analgesic (initiation of burning pain and erythema) are due to TRPV1-mediated local release of vasoactive neuropeptides (Marincsak et al., 2008).

TRPV1 Antagonists

The most advanced knowledge on the pharmacological modulation of a TRP channel has been obtained for TRPV1, because of the relevance of this protein for the management
of chronic pain, migraine, and gastrointestinal disorders (Szallasi et al., 2007). As a result, numerous companies have initiated programs to discover TRPV1 modulators, identifying many novel and potent antagonists. Only the best-documented groups of synthetic antagonists are discussed here, dividing the various chemotypes into two major classes. The classic antagonists are characterized by the presence of a carbonyl group of the ester-, amide-, urea-, or thiourea-type that links two moieties, generally with different polarity. In the nonclassic antagonists, the carbonyl group is either present as part of a heterocyclic ring (e.g., 4-aminooxazolines) or is unrecognizable.

Despite the structural heterogeneity of TRPV1 antagonists, a general model for their binding interaction with TRPV1 antagonists has been proposed (Szallasi et al., 2007). In brief, the unifying structural feature of TRPV1 antagonists is the presence of a central hydrogen-bond acceptor/donor motif flanked by a lipophilic side chain on one side and a more polar aromatic group that incorporates a hydrogen-bond acceptor on the other. A hydrogen-bonding motif is present in many known TRPV1 antagonist structures. In the classic antagonists, the central core can act as an H-bonding donor and acceptor, whereas in some nonclassic antagonists, it can only act as an H-bonding acceptor. In the polar arm, the placement of mono- or bicyclic-aryl and heteroaryl rings with a properly positioned hydrogen-bond acceptor are critical to both potency and drug-likeness. In the apolar arm, the placement of lipophilic substituents like a para-trifluoromethyl or a para-t-butyl is crucial for potency, whereas the relevance of the aromatic ring in both arms is presumably related to the possibility of a π–π interaction with the critical tyrosine group present in the vanilloid binding site.

**Competitive Antagonists: Naturally Occurring TRPV1 Antagonists.** TRPV1 antagonists are rare within natural products, in sharp contrast with the variety of agonists reported. The naturally occurring TRPV1 antagonists in nature, in which these compounds seemingly act as a feeding deterrent. The naturally occurring TRPV1 antagonists discovered so far are structurally unrelated to the synthetic inhibitors and show only modest potency. The sesquiterpene lactone thapsigargin (23) is the irritant principle of *Thapsia gargarica* L., a plant used in traditional and folk medicine as an anti-inflammatory agent. Thapsigargin behaves not only as an ultratent (subnanomolar) sarco(endoplasmic reticulum Ca$^{2+}$ ATPase inhibitor but also, paradoxically, as a TRPV1 antagonist (Table 2). No attempt has been made to dissect these activities and to assess the value of thapsigargin as a template to design TRPV1 antagonists (Tóth et al., 2002). Yohimbine (24), an indole alkaloid from the tree *Pausinystalia yohimbe* Pierre (formerly known as *Corynanthe yohimbe*) inhibits TRPV1 and the firing activity of DRGs exposed to capsaicin (Dessaint et al., 2004).

**Endogenous TRPV1 Antagonists.** Dynorphins, natural arginine-rich brain peptides that bind to κ-opioid receptors, are potent blockers of TRPV1, an activity that might contribute to their analgesic profile (Dessaint et al., 2004). Adenosine has also been proposed as an endogenous direct antagonist of TRPV1 (Puntambekar et al., 2004), whereas various dietary ω-3 fatty acids like eicosapentaenoic and linolenic acids inhibit TRPV1 and might be beneficial for the treatment of pain (Matta et al., 2007). More recently, the endogenous fatty acid amide hydrolase inhibitor N-arachidonoyl serotonin (25) has been shown to cause a direct block of TRPV1 (IC$_{50}$ ~ 40 nM) and to inhibit the generation of anandamide. This dual effect represents a promising treatment against acute and chronic peripheral pain (Maione et al., 2007). Finally, polyamines have been reported to block TRPV1 channels. Thus, putrescine, spermidine, and spermine permeate TRPV1 with P$_{Na}$ values between 3 and 16, and spermine reduced the single-channel conductance from 96 to 49 pS (Ahern et al., 2006).

<table>
<thead>
<tr>
<th>Group</th>
<th>Compound</th>
<th>Compound Number</th>
<th>IC$_{50}$ (M)</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naturally occurring</td>
<td>Thapsigargin</td>
<td>23</td>
<td>10$^{-5}$–10$^{-6}$</td>
<td>Rat</td>
<td>Tóth et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>Yohimbine</td>
<td>24</td>
<td>10$^{-5}$–10$^{-4}$</td>
<td>Rat</td>
<td>Dessaint et al. (2004)</td>
</tr>
<tr>
<td>1,3-Di(arylalkyl)thioureas</td>
<td>Capsazepine</td>
<td>22</td>
<td>10$^{-7}$–10$^{-6}$</td>
<td>Rodent</td>
<td>Caterina et al. (1997)</td>
</tr>
<tr>
<td></td>
<td>Compound</td>
<td>26</td>
<td>10$^{-5}$</td>
<td>Rat</td>
<td>Lee et al. (2003)</td>
</tr>
<tr>
<td></td>
<td>JYL1421</td>
<td>27</td>
<td>10$^{-8}$</td>
<td>Rat</td>
<td>Wang et al. (2002)</td>
</tr>
<tr>
<td>Iodinated vanillyl derivatives</td>
<td>5-iodoRTX</td>
<td>11b</td>
<td>10$^{-9}$</td>
<td>Rat</td>
<td>Wahl et al. (2001)</td>
</tr>
<tr>
<td></td>
<td>BCTC</td>
<td>28</td>
<td>10$^{-9}$</td>
<td>Rat</td>
<td>Pomonis et al. (2003)</td>
</tr>
<tr>
<td></td>
<td>A-425619</td>
<td>29a</td>
<td>10$^{-9}$</td>
<td>Rat</td>
<td>McDonald et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>SB-452533</td>
<td>31</td>
<td>10$^{-9}$–10$^{-7}$</td>
<td>Human</td>
<td>Rami et al. (2004)</td>
</tr>
<tr>
<td></td>
<td>ABT-102</td>
<td>32</td>
<td>10$^{-9}$</td>
<td>Human</td>
<td>Surowy et al. (2008)</td>
</tr>
<tr>
<td>Cinnamides</td>
<td>SB-366791</td>
<td>33</td>
<td>10$^{-9}$</td>
<td>Human &amp; rat</td>
<td>Patwardhan et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>AMG-9810</td>
<td>34</td>
<td>10$^{-8}$</td>
<td>Human &amp; rat</td>
<td>Doherty et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>SB-782443</td>
<td>36</td>
<td>10$^{-9}$–10$^{-7}$</td>
<td>Human &amp; rat</td>
<td>Westaway et al. (2008b)</td>
</tr>
<tr>
<td>Carboxamides</td>
<td>Compound</td>
<td>38</td>
<td>10$^{-9}$–10$^{-7}$</td>
<td>Human &amp; rat</td>
<td>Westaway et al. (2008b)</td>
</tr>
<tr>
<td>Nonclassic antagonists</td>
<td>Imidazole derivatives</td>
<td>Compound</td>
<td>39</td>
<td>10$^{-9}$</td>
<td>Rat</td>
</tr>
<tr>
<td></td>
<td>AMG517</td>
<td>40</td>
<td>10$^{-10}$</td>
<td>Rat</td>
<td>Gavva et al. (2007)</td>
</tr>
<tr>
<td>Noncompetitive</td>
<td>Ruthenium Red</td>
<td>41a</td>
<td>10$^{-7}$</td>
<td>Rat</td>
<td>García-Martínez et al. (2000)</td>
</tr>
<tr>
<td></td>
<td>AG 489</td>
<td>43</td>
<td>10$^{-9}$</td>
<td>Rat</td>
<td>Kitaguchi and Swartz (2005)</td>
</tr>
<tr>
<td></td>
<td>DD161515</td>
<td>43</td>
<td>10$^{-7}$–10$^{-6}$</td>
<td>Rat</td>
<td>García-Martínez et al. (2002)</td>
</tr>
</tbody>
</table>
discovery was therefore serendipitous. This program, to date the most comprehensive one focusing on capsaicin, was based on the recognition that the structure of this natural alkaloid can be divided into three moieties: the aromatic and hydrogen bonding A ring, the lipophilic C tail, and the carbonyl-containing B-linker (Suh and Oh, 2005). In principle, capsaazepine can be considered as a conformationally restricted capsaicin analog in which the amide bond of the natural product is replaced by a thiourea moiety and in which the presence of a tether between the aromatic A ring and the B-linker forces the catecholic aromatic moiety into an orthogonal orientation with respect to the thiourea bond. Pharmacological studies showed that capsaazepine exhibited low metabolic stability and poor pharmacokinetic properties in rodents, thus preventing its clinical development (Walker et al., 2003). The tether was not critical for activity, because powerful capsaicinoid antagonists devoid of this structural feature were developed, with 1,3-diarylalkylthioureas emerging as one of the most promising nonvanillloid class of TRPV1 antagonists. These compounds are endowed with excellent therapeutic potential in pain regulation, with an IC_{50} value generally lower than 100 nM (Suh and Oh, 2005; Suh et al., 2005; Chung et al., 2007). Within these compounds, the replacement of the guaiaeryl moiety of capsaicinoids with a 3-fluoro-4-sulfonylamido group was critical to revert biological activity. This, coupled to the design of C-region

... (Suh and Oh, 2005; Suh et al., 2006). It is noteworthy that 6-iodoRTX is a partial agonist, as an impurity (Ech-Chahad et al., 2011c) was identified as a highly active TRPV1 antagonist worthy of further development (Gore et al., 2007).

The structural diversity of this class of antagonists is evident in the vast number of molecules that have been synthesized and tested. The development of nonclassic antagonists has made it possible to target pain pathways in a more selective and specific manner, leading to the discovery of compounds with promising clinical potential.

**Imidazole Derivatives.** Starting from a 4,6-disubstituted benzimidazole lead structure, a series of 4,5-bisarylimidazoles capable to block both capsaicin- and acid-induced calcium influx in TRPV1-expressing Chinese hamster ovary cells were obtained. Imidazole (39) was identified as a highly potent (IC_{50} ~ 10^{-9} M) and orally bioavailable TRPV1 antagonist worthy of further development (Gore et al., 2007).
cyclic cores was investigated, ranked in terms of activity in this sequence: 5-isoquinoline > 8-quinoline = 8-quinazoline > 8-isoquinoline = cinnoline = phthalazine = quinoxaline = 5-quinoline (Blum et al., 2008). Of particular relevance is AMG517 (40), a compound that lacks any recognizable carbonyl motif. This compound potently blocks capsaicin, proton, and heat activation of TRPV1 in vitro, inhibits capsaicin-induced flinch in rats in vivo, and shows, apart from hyperthermia, a good tolerability profile (Gavva et al., 2007).

**Noncompetitive Antagonists (Pore Blockers).** Ruthenium red (RR) is a noncompetitive pan inhibitor of all TRP channels. This compound presumably interacts not only with the ligand binding site of TRPs but apparently also blocks its aqueous pore. RR binds TRPV1 with high potency (Table 2) in a voltage-dependent manner (i.e., inward currents are efficiently blocked but not outward currents) (García-Martínez et al., 2000). Commercial RR is a mixture of various ruthenium derivatives, but surprisingly, its active component has not yet been characterized. Tetrabutylammonium (TBA) blocks the conductive pore of TRPV1. TBA belongs to a family of classic potassium channel blockers that have been widely used as tools for determining the localization of the activation gate and the properties of the pore of several ion channels. TBA blocks TRPV1 in a voltage-dependent fashion, consistent with being an open-state blocker and interfering with the closing of an activation gate located cytoplasmically (Oseguera et al., 2007). Indeed, TRPV1 is permeable to organic cationic dyes and aminoglycoside antibiotics, suggesting the existence of a large pore (Meyers et al., 2003; Mydral and Stegger, 2005). The pore block and the divergent permeability of TRPV1 depend on the negatively charged residues described above within the pore region of the protein (García-Martínez et al., 2000).

Robust TRPV1 inhibitory activity was found in the venom from the North American funnel web spider, Agelenopsis aperta. Fractionation of the venom resulted in the purification of two acylpolyamine toxins, AG489 and AG505 (41a and 41b, respectively), which both inhibit TRPV1 channels from the extracellular side of the membrane. AG489 (Table 2) was found to inhibit TRPV1 in a voltage-dependent way, with relief from inhibition being observed at positive voltages, an observation consistent with a model in which the toxin inhibits the channel through a pore-blocking mechanism (IC_{50} ~ 33 nM at ~ 40 mV). Negatively charged residues in the pore vestibule have indeed been identified as the AG489 binding site. Mutations of these site (Glu636, Asp646, Glu651, and Asn588) result in weakening of the block, whereas mutations of Tyr627 and Cys636 in the pore region enhance the toxin affinity (Kitaguchi and Swartz, 2005).

Because arginine-rich hexapeptides like RRRRW-W-NH₂ block TRPV1 channels expressed in *Xenopus laevis* oocytes in a nonselective manner (Himmel et al., 2002), various polyethylene tetraamines were investigated as TRPV1 channel blockers. These studies identified methoctramine (42), a muscarinic M2 receptor antagonist, as a noncompetitive capsaicin antagonist with an IC_{50} value of 2 μM and notable voltage-dependent block (Mellor et al., 2004). Finally, screening of a library of tripeptoid N-alkylglycines identified DD161515 (43, Table 2) and DD191515 as TRPV1 blockers with micromolar potency and moderate voltage-dependence (García-Martínez et al., 2002).

An interesting mechanism of analgesia has been developed capitalizing on TRPV1 pore permeability. Thus, the membrane-impermeable Na⁺ channel blocker QX-314 can permeate cells through capsaicin-activated TRPV1. Under these conditions, it can block from the inner site the Na⁺ channels in DRG neurons, preventing the generation of an action potential, and behaving as a long-lasting analgesic (Binshtok et al., 2007).

**TRPV2**

TRPV2 has been proposed as a potential pain target both for its sequence similarity to TRPV1 (50% identical) and for its activation by noxious high temperatures (>52°C) (Caterina et al., 1999). This view is supported by the finding that TRPV2 is widely expressed in medium to large diameter Aδ mechanosensitive and thermosensitive neurons in the rat dorsal root ganglia (Caterina et al., 1999), trigeminal ganglia (Ichikawa and Sugimoto, 2000), and the spinal cord (Lewinter et al., 2004).

**TRPV2 Agonists**

TRPV2 is activated by noxious heat, with an activation threshold greater than 52°C (Caterina et al., 1999) and by a number of exogenous chemical ligands, but ligand and thermal activation show species specificity. For example, although noxious heat (up to 53°C) and the nonselective agonist 2-APB activate rat and mouse TRPV2, human TRPV2 does not respond to 2-APB (up to 1 mM) or to elevated temperatures (up to 53°C; (Neeper et al., 2007). Analysis of chimeric constructs of mouse and human TRPV2 channels showed that the molecular determinants of 2-APB sensitivity are localized in the intracellular N and C termini. Further experiments showed that human TRPV2 exerts, with an unknown mechanism, a dominant-negative effect on 2-APB activation of native rodent TRPV2 channels (Juvín et al., 2007). Another phenylborate, DPBA, is also able to activate mouse TRPV2 with similar EC_{50} values (Juvín et al., 2007). Rat TRPV2 is activated by the uricosuric agent probenecid (44, Table 3), and five other sensory thermoTRPs (TRPV1,

<table>
<thead>
<tr>
<th>Group</th>
<th>Compound</th>
<th>Compound Number</th>
<th>Conc. R</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activators</td>
<td>Probenecid</td>
<td>44</td>
<td>10^{-5}</td>
<td>Rat</td>
<td>Bang et al. (2007)</td>
</tr>
<tr>
<td></td>
<td>Cannabidiol</td>
<td>45</td>
<td>10^{-6}</td>
<td>Human and rat</td>
<td>Qin et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>THC</td>
<td>46</td>
<td>10^{-5}</td>
<td>Human and rat</td>
<td>Qin et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>Cannabidiol</td>
<td>47</td>
<td>10^{-4}</td>
<td>Human and rat</td>
<td>Qin et al. (2008)</td>
</tr>
<tr>
<td>Inhibitors</td>
<td>SKF96365</td>
<td>48</td>
<td>10^{-5}</td>
<td>Mouse</td>
<td>Juvín et al. (2007)</td>
</tr>
</tbody>
</table>
TRPV3, TRPV4, TRPM8, and TRPA1) failed to show a response to this drug (Bang et al., 2007). Very recently, several novel cannabinoid rat TRPV2 modulators were identified. Cannabidiol (45), a nonpsychoactive compound, was found to be a more robust and potent agonist (EC50 ~4 μM) than the psychoactive agent Δ9-tetrahydrocannabinol (46), the main psychoactive substance found in Cannabis sativa L. (EC50 ~14 μM) and cannabiol (47, EC50 ~78 μM) (Table 3) (Qin et al., 2008). TRPV2 has been proposed as a potential pain target, but very little is known about its activation mechanism or possible candidates for specific or endogenous TRPV2 activators.

Sensitizers. Although no selective exogenous or endogenous activators of TRPV2 have been identified to date, evidence has been growing that translocation may be an important mechanism for TRPV2 functional activation. Growth factors up-regulate TRPV2 expression and function by promoting its translocation from the intracellular pools to the plasma membrane, in which it demonstrates constitutive activity (e.g., insulin-like growth factor-1) (Kanzaki et al., 1999; Boels et al., 2001; Iwata et al., 2003). Heat and phoshatidylinositol-3 (PI3) kinase also promote TRPV2 membrane insertion, whereas PI3 kinase inhibition reduces TRPV2 membrane insertion (Penn et al., 2006). In accordance with this scenario, the PI3 kinase inhibitors LY29340011 could block the translocation of TRPV2 to the plasma membrane (Nagasawa et al., 2007).

TRPV2 Antagonists

Despite the possible role of TRPV2 as a potential pain target, few specific blockers have been identified yet. Some general blockers like RR and trivalent cations such as La3+ and Gd3+ have been described as blockers of TRPV2 (Leffler et al., 2007). SKF96365 (48) and the diuretic amiloride (49) also behave as efficient blockers (Table 3). In addition, the potassium channel blockers tetraethylammonium, 4-aminoopyridine, and 1-(2-trifluoromethyl) phenyl imidazole were all found to inhibit TRPV2 activation (Juvin et al., 2007). Also the monoterpene aldehyde citral (50) inhibited, in a voltage-independent way, the 2-APB-activated evoked activity of TRPV2 (Kd ~534 μM) (Stotz et al., 2008).

TRPV3

TRPV3 was cloned by using its sequence homology to other heat-activated TRP channels, and shares 40% identity with TRPV1. TRPV3 shows threshold in the physiological temperatures range of 32 to 39°C and can also be activated by 2-APB and camphor (13) (Nilius and Mahieu, 2006). In humans, TRPV3 has been reported to be present in pain pathways, including DRG and TG neurons, spinal cord, keratinocytes, and brain (Xu et al., 2002). However, in mouse and rat, the distribution of TRPV3 is more controversial (Peier et al., 2002).

TRPV3 Agonists

TRPV3 is highly expressed in the skin, tongue, and nose (Xu et al., 2002) and is the target for several plant-derived aromatic agents and for skin sensitization. TRPV3 is activated by a number of exogenous ligands, including natural irritants (e.g., camphor (13); Moqrich et al., 2005), thymol (51) from thyme, and eugenol (9) from clove and might be involved in the anesthetic, analgesic, and antipruritic properties of these compounds (Vogt-Eisele et al., 2007) (Table 4). Vanillin (52a), the active ingredient of vanilla (Vanilla planifolia Jacks. ex Andrews), weakly activates TRPV3, whereas the synthetic flavor ethylvanillin (52b), the homolog of the natural product, activates TRPV3 much more potently (Xu et al., 2006). Surprisingly, a recent report showed that menthol (53) from peppermint (Mentha piperita L.), a popular cooling agent and TRPM8 activator, also binds to and activates TRPV3 (Vogt-Eisele et al., 2007). The disinfectant cresol (methylphenol) also activates TRPV3. Solutions of this simple phenol are used as household cleaners and disinfectants, perhaps most famously under the trade name Lysol (Reckitt Benckiser, Parsippany, NJ). Cresol was also promoted as a disinfesting vaginal douche in mid-20th century America. It also occurs in foods, wood and tobacco smoke, crude oil, and coal tar (Vogt-Eisele et al., 2007).

The membrane diterpenoid incense acetate (54), a constituent of frankincense, is a potent TRPV3 agonist that causes anxiolytic-like and antidepressive-like behavioral effects in wild-type mice (Table 4). These behavioral effects were not evidenced in TRPV3−/− mice. Incense acetate activates TRPV3 channels also in native keratinocytes, but only modest effects were observed on TRPV1, TRPV2, and TRPV4 (Moussaieff et al., 2008). The synthetic compounds 2-APB and diphenylboric anhydride (DPBA) can also activate TRPV3. In single-channel analysis of inside-out membrane patches excised from TRPV3-expressing cells, 1 μM 2-APB evoked single-channel openings (Chung et al., 2004). The 2-APB analog DPBA and 2,2-diphenyltetrahydrofuran (DPTHF) also influences TRPV3. DPBA activates TRPV3 in a similar manner as 2-APB (Table 4), whereas DPTHF has an opposite action, blocking TRPV3. Apparently, a structural feature important for activation of TRPV3 lacks in DPTHF.

### Table 4

<table>
<thead>
<tr>
<th>Group</th>
<th>Compound</th>
<th>Compound Number</th>
<th>EC50</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activators</td>
<td>Camphor</td>
<td>13</td>
<td>10−4</td>
<td>Human and mouse</td>
<td>Moqrich et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>Thymol</td>
<td>51</td>
<td>10−4</td>
<td>Human and mouse</td>
<td>Xu et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>Menthol</td>
<td>53</td>
<td>10−4</td>
<td>Murine</td>
<td>Macpherson et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>Eugenol</td>
<td>52a</td>
<td>10−5</td>
<td>Human and mouse</td>
<td>Xu et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>Incensole acetate</td>
<td>54</td>
<td>10−5</td>
<td>Mouse</td>
<td>Moussaieff et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>2-APB</td>
<td></td>
<td>10−6</td>
<td>Mouse</td>
<td>Chung et al. (2004)</td>
</tr>
</tbody>
</table>
resulting in inhibition even though it binds to a “stimulatory site” (Chung et al., 2005).

Very recently, evidence was found that 2-APB activation of TRPV3 is separable from other activation mechanisms and depends on two cytoplasmic residues (Hu et al., 2009). Thus, Hu and coworkers (2009) found two residues (His426 and Arg596) specifically required for sensitivity of TRPV3 to 2-APB but not to camphor or voltage (Hu et al., 2009). Chicken TRPV3 is weakly sensitive to 2-APB, and the equivalent residue at 426 is an asparagine. Mutating this residue to histidine induced 2-APB sensitivity of chicken TRPV3 to levels comparable with those of other TRPV3 orthologs. The cytoplasmic C-terminal mutation R696K in the TRP box displayed 2-APB-specific deficits only in the presence of extracellular calcium, suggesting involvement in gating. Mutating these two residues in TRPV4, a 2-APB-insensitive channel, to TRPV3 sequences was sufficient to induce TRPV3-like 2-APB sensitivity (Hu et al., 2009).

Sensitizers. TRPV3 is also sensitized and/or directly activated by endogenous ligands, including downstream elements of the inflammatory cascade, such as unsaturated fatty acids (e.g., arachidonic acid) and protein kinases (e.g., PKC) (Hu et al., 2006). TRPV3 would be expected to be basally active at body temperature. However, TRPV3 activity may be further enhanced under inflammatory conditions.

TRPV3 Antagonists

There are very few potent and selective inhibitors of TRPV3. The TRPV3 antagonist HC-001403 has been reported to be active in animal models of pain, like the rat complete Freund’s adjuvant inflammatory hyperalgesia, the formalin-induced flinching assay, and the thermal injury pain (Moran et al., 2007). Two other antagonists were recently reported. These compounds (GRC 15133 and GRC 17173) displayed potency in the low 100 nM range, with excellent selectivity in terms of TRPs binding and efficacy in inflammatory and nerve injury models (Guillapalli et al., 2008).

TRPV4

TRPV4 functions as a Ca$^{2+}$-entry channel that exhibits a surprising gating promiscuity. The channel can be activated by physical stimuli (cell swelling and innocuous warmth, ~27–35°C) and by chemical ligands. Endogenous chemical ligands (e.g., endocannabinoids and arachidonic acid metabolites) and small-molecule exogenous ligand from the pool of natural products (e.g., bisandrogropholide A, 55), natural product derivatives (e.g., α-phorbol esters, 56a–d), and fully synthetic compounds (e.g., GSK10116790A, 57) have been identified. TRPV4 is widely expressed in brain, central nervous system, kidney, bladder, vascular endothelium, keratinocytes, and multiple excitable and nonexcitable peripheral cell types (Nilius et al., 2004).

TRPV4 Agonists

TRPV4 was originally identified as a channel activated by hypotonic cell swelling (Liedtke et al., 2000; Strotmann et al., 2000; Wissenbach et al., 2000; Nilius et al., 2001b). Activation of TRPV4 by cell swelling is caused by PLA2 activation (Watanabe et al., 2003; Vriens et al., 2005). PLA2-mediated release of arachidonic acid from membrane lipids and subsequent metabolism of arachidonic acid by cytochrome P450 epoxygenase activity leads to the formation of epoxycosaatrienoic acids (EETs), which activate TRPV4 in a membrane-limited manner. Given the high ligand sensitivity, it does not seem unreasonable to assume that TRPV4 has also endogenous ligands, but none of them has so far been identified (Nilius et al., 2003, 2004; Watanabe et al., 2003; Vriens et al., 2005).

Phorbol esters, like 4α-PDD (56a), bind TRPV4 in a very specific (lack of response in TRPV4-deficient mice; Vriens et al., 2005) and membrane-delimited manner (Watanabe et al., 2002; Vriens et al., 2004b). Activation by 4α-PDD is slow, suggesting that diffusion in the cell might be rate-limiting. In line with an intracellular mode of action, application of 4α-PDD from the cytoplasmic side of inside-out patches activates TRPV4. A tyrosine-serine motif located in the intracellular loop between the second and third transmembrane domain determines the responsiveness to 4α-PDD but not to hypotonic solutions or arachidonic acid. Furthermore, mutations of two hydrophobic residues in the central part of TM4 (Leu584 and Trp586) caused a severe reduction of the sensitivity of the channel to 4α-PDD and heat, whereas responses to cell swelling, arachidonic acid, and 5,6-EET remained unaffected. Conversely, the mutation of two residues in the C-terminal region of TM4 (Tyr591 and Arg594) affected channel activation of TRPV4 by all stimuli, suggesting an involvement in channel gating rather than in interaction with ligands. Comparison of the responses of wild-type and mutant TRPV4 with a series of 4α-phorbol diesters established a critical role for the length of the acyl moiety that is optimal for 6 and 10 carbons (Vriens et al., 2007) (Table 5). The 4α-configuration is apparently not essential for channel activation because 4β-PDD (56b) could activate TRPV4 with potency similar to that of 4α-PDD (Nilius et al., 2004), whereas phorbol-12-myristate-13-acetate (PMA, 58), the archetypal tumor-promoting PKC activator, could activate TRPV4, albeit with a 10- to 50-fold lower potency than 4α-PDD. In sharp contrast to the structure-activity relationships for PKC activation by phorbol esters, removal of the 4-hydroxyl and conversion to cage compounds from the luminer series were not critical for the activity of 4α-phorbol diesters.

### Table 5

<table>
<thead>
<tr>
<th>Group</th>
<th>Compound</th>
<th>Compound Number</th>
<th>EC$_{50}$</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activators</td>
<td>Arachidonic Acid</td>
<td>5,6-EET</td>
<td>4α-PDD</td>
<td>GSK10116790A</td>
<td>10$^{-5}$</td>
</tr>
<tr>
<td></td>
<td>5,6-EET</td>
<td>55</td>
<td>4α-PDD</td>
<td>GSK10116790A</td>
<td>10$^{-5}$</td>
</tr>
<tr>
<td></td>
<td>4α-PDD</td>
<td>56a</td>
<td>4α-PDD</td>
<td>GSK10116790A</td>
<td>10$^{-5}$</td>
</tr>
<tr>
<td></td>
<td>BAA</td>
<td>57</td>
<td>4α-PDD</td>
<td>GSK10116790A</td>
<td>10$^{-5}$</td>
</tr>
</tbody>
</table>
Conversely, two ester groups of similar length were necessary for activity (Vriens et al., 2007).

TRPV4 is also activated by the dimeric diterpenoid bisandrogrophalidine A (BAA, 55) (Table 5) from the Indian medicinal plant Andrographis paniculata. BAA functions also in cell-free inside-out patches, indicating a membrane-delimited action (Smith et al., 2006). Evidence was provided that the TM3 to TM4 region of TRPV4 forms an important site for channel activation by BAA. In particular, mutations at positions Leu584 and Trp586 in TM4 strongly affect channel activation by BAA (Vriens et al., 2007).

A novel very potent activator for TRPV4 has been reported (GSK1016790A, 57) (Thronelee et al., 2008). This compound produced dramatic and complex cardiovascular effects associated with endothelial barrier failure, eventually leading to circulatory collapse, in mouse, rat, and dog (Willette et al., 2008). TRPV4 is highly expressed in the endothelium, where it is involved in intracellular Ca²⁺ homeostasis and the regulation of cell volume (Vriens et al., 2005). The discovery that its inapposite activation leads to massive disruption of microvascular permeability suggests that TRPV4 might be associated with edema and microvascular congestion.

**Sensitizers.** TRPV4 can be sensitized to activation by proteases generated under inflammation conditions, like the PAR2. PAR2 agonists sensitize activation of TRPV4 by 4aPDD and hypotonic cell swelling probably via PLCβ, PKA, PKC, and protein kinase D (Grant et al., 2007; Surprenant, 2007).

In native ciliated epithelial cells, the PLA2-EET primary pathway and the PLC pathway, both activated by ATP, cooperate and support TRPV4 gating, whereas IP₃ per se, not an agonist, sensitizes TRPV4 to EET. Coimmunoprecipitation assays indicated a physical interaction between TRPV4 and IP₃R3. TRPV4 channels and intracellular store Ca²⁺ channels are both required to initiate and maintain the oscillatory Ca²⁺ signal triggered by high viscosity and hypertonic stimuli that do not reach a threshold level of PLA2 activation (Fernandes et al., 2008).

**TRPV4 Antagonists**

Besides the classic TRP inhibitors RR that reversibly inhibits inward but not outward TRPV4 currents (Watanabe et al., 2002), Gd³⁺, and La³⁺, two new TRPV4 antagonists with micromolar (RN-1734) and nanomolar (RN-9893) potency with selectivity versus other thermo-TRPs, were described. RN-9893 was also reported to possess good pharmacokinetic properties, but no in vivo data have been published (Broad et al., 2009). Citral (50) from lemongrass oil, a compound commonly used to repel insects, inhibits TRPV4 activity in a voltage-independent way (IC₅₀ ~32 μM) (Stotz et al., 2008).

**TRPV5 and TRPV6**

Compared with TRPV1-V4, TRPV5 and its highly homologous TRPV6 are only distantly related, as evident from the phylogenetic tree depicted in Fig. 1. Unsurprisingly, they also show somewhat different functional properties, whose hallmark is the high Ca²⁺ selectivity. Expression profiling of TRPV5 and TRPV6 showed expression in kidney, small intestine, placenta, prostate, pancreas, salivary gland, brain, colon, and rectum (Hoenderop et al., 1999). In general, TRPV5 expression seems to be typical of kidney, whereas TRPV6 is predominantly expressed in small intestine and prostate (Hoenderop et al., 2000). Currents through TRPV5 and TRPV6 are strongly inwardly rectified and highly Ca²⁺-selective (P_Ca/P_Na > 100).

**TRPV5 and TRPV6 Agonists**

No direct activator of TRPV5 and TRPV6 has so far been identified. TRPV5 and TRPV6 channels are constitutively active when inserted into the plasma membrane. Regulation most probably occurs by variation of the channel density on the plasma membrane. Expression of TRPV5 is influenced by 1,25-dihydroxy vitamin D₃ (Yamauchi et al., 2005), the Ca²⁺ binding protein S100A10, and annexin II (van de Graaf et al., 2006). Calmodulin binds to both TRPV5 and TRPV6 in a Ca²⁺-dependent fashion (Lambers et al., 2004) and supports, at least, the activation of TRPV6. Extracellular alkalization causes TRPV5 accumulation in subplasmalemmal vesicles. From this pool, TRPV5 can be rapidly recruited into the plasma membrane (Lambers et al., 2007).

An important regulatory pathway comprises the tissue serine protease kallikrein. Kallikrein activates the bradykinin receptor-2, which in turn activates PKC dependently on diacylglycerol via PLCβ. Phosphorylation of TRPV5 increases membrane insertion of the channel and delays retrieval (Gkika et al., 2006). The PKC activator 1-octyl-acetyl-sn-glycerol (OAG) also increased TRPV5 surface abundance. The OAG-mediated increase of TRPV5 was prevented by preincubation with specific PKC inhibitors. Knockdown of caveolin-1 also prevented the increase of TRPV5 by OAG. Parathyroid hormone (PTH) increased TRPV5 current density in cells expressing TRPV5 and type 1 PTH receptor. The increase caused by PTH was prevented by PKC inhibitor, mutation of Ser299/Ser654, or knockdown of caveolin-1. This mechanism of regulation by PKC may contribute to the short-term stimulation of TRPV5 and renal Ca²⁺ reabsorption by PTH (Cha et al., 2008).

TRPV5 is highly regulated by WNK4, a protein serine/threonine kinase whose gene mutations cause familial hyperkalemic hypertension. Expression of WNK4 increases surface expression of TRPV5 and therefore modulates calcium reabsorption mediated by this channel (Jiang et al., 2007).

The pro-urine hormone klotho can stimulate TRPV5 and TRPV6 by N-oligosaccharide hydrolysis. Klotho is a β-glucuronidase that hydrolyzes extracellular sugar residues on TRPV5, entrapping the channel in the plasma membrane. Klotho effects are primarily restricted to the epithelial Ca²⁺ channels TRPV5 and TRPV6 (Chang et al., 2005; Schoeber et al., 2007; Lu et al., 2008).

**TRPV5 and TRPV6 Antagonists**

The most effective inhibitors of currents through TRPV5 described so fare are RR and the antifungal azole econazole (59), with IC₅₀ values between 0.1 and 1 μM. The divalent cation current block profile for TRPV5 is Pb²⁺ = Cu²⁺ > Zn²⁺ > Co²⁺ > Fe²⁺, with IC₅₀ values between 1 and approximately 10 μM (Nilius et al., 2001a). It is noteworthy that TRPV6 can be blocked by RR but has a 100-fold lower affinity for RR (IC₅₀ ~9 μM) than TRPV5 (Nilius et al., 2001a). Ca²⁺-induced inactivation occurs at hyperpolarized potentials in the presence of extracellular Ca²⁺. Half-maximal inactivation by [Ca²⁺]i occurs at a concentration of ~100 nM. TRPV6 is Ca²⁺-dependently inactivated, a process trig-
tered by Ca$^{2+}$-dependent PLC activation and depletion ofPIP2. U73122 and edofesine induce sustained TRPV6 activation in a duodenal sac assay. Thus, PLC modulators can be used as novel TRPV6 Ca$^{2+}$ reabsorption modulators (Thyagarajan et al., 2009).

Blockade of TRPV5 and TRPV6 by extracellular Mg$^{2+}$ is voltage-dependent and critically depends on a single aspartate residue in the selectivity filter of the TRPV5/6 pore. Intracellular Mg$^{2+}$ also exerts a voltage-dependent block that is alleviated by hyperpolarization and contributes to the time-dependent activation and deactivation of TRPV6-mediated monovalent cation currents (Voets et al., 2001, 2003).

TRPV5 is inhibited by binding protons to the extracellular Glu522. In addition, mutation of the pore helix residue E535Q further enhances inhibition by H$^+$ by shifting the pKa value for inhibition toward more alkaline values. This mechanism may contribute to hypercalcemia with high acid load (Yeh et al., 2006).

TRPV6 interacts with the protein tyrosine phosphatase 1B and is probably inhibited by Ca$^{2+}$ via an intermediate reactive oxygen species. Inhibition of tyrosine dephosphorylation by protein tyrosine phosphatase 1B inhibition causes a maintained Ca$^{2+}$ influx via TRPV6, thus inducing a positive feedback (Sternfeld et al., 2005; Bogeski et al., 2006).

### Conclusion

Iont channels of the TRPV subfamily form an important aspect of the sensory mechanism of animals. Indeed, it has been shown that one part of the TRPV subfamily, namely TRPV1 to TRPV4, reacts to thermal, mechanical, and/or painful stimuli. The properties as nociceptors qualify TRPV1 to TRPV4 as important tools for the treatment of pain. TRPV1, perhaps the most important signal integrator in sensory nociceptors, is well established as an intriguing novel target for the treatment of pain. TRPV1 antagonism represents one of several novel mechanistic approaches to pain relief on route to the next-generation analgesic, and preclinical data indicate that TRPV1 antagonists might also provide a useful therapeutic option for urinary incontinence, pancreateitis, cough, and migraine (Szallasi et al., 2006). Most anti-inflammatory drugs under development target the propagation and transmission of signals to the spinal cord, whereas TRPV1 antagonists target the generation of the nociceptive stimulus.

In this review, we clearly illustrate that TRPV channels are sensitive to modulation by exogenous small molecules. However, our limited knowledge of their endogenous ligands make them still substantially “orphan” receptors. Furthermore, except for TRPV1, the pharmacology of these channels is sparse, and selective molecular tools (ligands, blockers, and sensitizers) are missing but urgently required. In addition, information on the regions and amino acids involved in TRPV function is still missing. Because members of the TRPV family are critical players in peripheral nociception, a better knowledge of the ligand binding region could be used to rationally design novel antinociceptive or anti-inflammatory agents, and crystallographic analysis could shed light on the structural determinants of TRPV1 functionally. Finally, as our knowledge on the physiology and regulation of vanillloid receptors increases, so does the clinical relevance of the pharmacological manipulation of these ion channels.

### Acknowledgments

We thank Dra. T. Voets, G. Owsianik, and K. Talavera for helpful suggestions and criticisms.

### References


